SPRING BANK PHARMACEUTICALS, INC. (NASDAQ:SBPH) Files An 8-K Other Events
Item 8.01 Other Events.
On June 21, 2017, Spring Bank Pharmaceuticals, Inc. (the Company)
issued a press release announcing the commencement of an
underwritten public offering of its common stock to a shelf
registration statement filed on Form S-3 (File No. 333-218399)
with the Securities and Exchange Commission, which was declared
effective on June 12, 2017. A copy of the press release is
attached hereto as Exhibit 99.1 and is incorporated herein by
reference.
On June 21, 2017, the Company filed with the Securities and
Exchange Commission a preliminary prospectus supplement to its
effective shelf registration statement on Form S-3 (the
Preliminary Prospectus Supplement) to Rule 424 under the
Securities Act of 1933, as amended, relating to the
aforementioned proposed public offering of shares of the Companys
common stock. The Preliminary Prospectus Supplement contains an
updated summary description of the Companys business in the
section entitled Prospectus Supplement Summary, which is attached
hereto as Exhibit 99.2 and incorporated herein by reference.
This Current Report on Form 8-K, including the Exhibit hereto,
shall not constitute an offer to sell or the solicitation of an
offer to buy any securities of the Company, which is being made
only by means of a written prospectus meeting the requirements of
Section 10 of the Securities Act of 1933, as amended, nor shall
there be any sale of the Companys securities in any state or
jurisdiction in which such offer, solicitation or sale is not
permitted.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press release dated June 21, 2017, announcing a proposed |
|
99.2 |
Prospectus Supplement Summary of Spring Bank |
Spring Bank Pharmaceuticals, Inc. ExhibitEX-99.1 2 sbph-ex991_7.htm OFFERING PRESS RELEASE sbph-ex991_7.htm Exhibit 99.1 Spring Bank Pharmaceuticals Announces Proposed Public Offering of Common Stock HOPKINTON,…To view the full exhibit click here About SPRING BANK PHARMACEUTICALS, INC. (NASDAQ:SBPH)
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company’s SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. It also focuses on the use of SB 9200 in other viral diseases, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and latency and hepatitis delta virus (HDV), conducting preclinical research of additional SMNH product candidates or compounds as antiviral therapies and conducting early-stage research programs.
